Table 1 Summary data and sensitivity analyses for placebo controlled trials
| Â | Â | Â | Success with | Â | Â | |
|---|---|---|---|---|---|---|
Parameter | Trials | Patients | treatment | placebo | Relative benefit (95% CI) | NNT (95% CI) |
All trials | 26 | 2853 | 993/1531 | 512/1322 | 1.6 (1.4 to 1.7) | 3.8 (3.4 to 4.4) |
Trial quality | Â | Â | Â | Â | Â | Â |
Quality score ≥3/5 | 23 | 2551 | 893/1375 | 443/1176 | 1.6 (1.5 to 1.8) | 3.7 (3.2 to 4.3) |
Validity score ≥9/16 | 24 | 2793 | 969/1501 | 508/1292 | 1.5 (1.4 to 1.7) | 4.0 (3.5 to 4.6) |
Quality score ≥3 and validity score ≥9 | 22 | 2511 | 876/1355 | 440/1156 | 1.6 (1.4 to 1.8) | 3.8 (3.3 to 4.4) |
Trial size | Â | Â | Â | Â | Â | Â |
   ≥40 patients per group | 15 | 2279 | 761/1234 | 400/1045 | 1.4 (1.3 to 1.6) | 4.3 (3.7 to 5.2) |
   <40 patients per group | 11 | 574 | 232/297 | 112/277 | 1.9 (1.6 to 2.2) | 2.7 (2.2 to 3.3) |
Efficacy by outcome type | Â | Â | Â | Â | Â | Â |
   preferred outcomes | 17 | 1941 | 676/1025 | 373/916 | 1.5 (1.3 to 1.6) | 4.0 (3.4 to 4.8) |
   lower prefernce outcomes | 9 | 912 | 317/506 | 139/406 | 1.7 (1.5 to 2.1) | 3.5 (2.9 to 4.5) |
Efficacy by topical NSAID | Â | Â | Â | Â | Â | Â |
   ketoprofen | 6 | 517 | 203/261 | 101/256 | 2.1 (1.7 to 2.5) | 2.6 (2.2 to 3.3) |
   ibuprofen | 5 | 365 | 112/183 | 67/182 | 2.0 (1.5 to 2.6) | 4.1 (2.9 to 6.9) |
   felbinac | 3 | 413 | 112/210 | 57/203 | 1.6 (1.2 to 2.2) | 4.0 (2.9 to 6.2) |
   piroxicam | 3 | 563 | 179/283 | 118/280 | 1.4 (1.1 to 1.7) | 4.7 (3.4 to 7.7) |
   indomethacin | 3 | 394 | 95/197 | 76/197 | 1.3 (0.99 to 1.6) | 10 (5.2 to infinity) |
Adverse events | Â | Â | Â | Â | Â | NNH 95% CI |
Local adverse events | 23 | 2741 | 65/1464 | 60/1277 | 1.6 (1.0 to 2.5) | Not calculated |
Systemic adverse events | 23 | 2685 | 40/1437 | 30/1248 | 1.4 (0.9 to 2.0) | Not calculated |
Adverse events withdrawals | 24 | 3011 | 13/1601 | 10/1410 | 1.6 (0.8 to 3.4) | Not calculated |